אפרמול
tree of life pharma ltd - paracetamol - טבליה תוססת - paracetamol 500 mg - paracetamol
renalguard console and renalguard single use set
a.m.i. technologies, ltd. - אחות - מחלקות לצנטורים והדמיה בחומרי ניגוד
microspheres for wound healing
polyheal ltd. - רופא - מיקרוספרות לטיפול בכיבים כרוניים
הקסוויקס 85 מג
igl medical ltd - hexaminolevulinate as hydrochloride - hexaminolevulinate as hydrochloride 85 mg/vial
מרכך טיפולי לשיער - health & beauty
א.ל. ארמן יצור תמרוקים בעמ - ריכוך השיער
אוקסאאר 50 מג
organon pharma israel ltd., israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to ocsaar is not recommended. renal protection in type-2 diabetic patients with proteinuria: ocsaar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of ocsaar on the primary deposite endpoint was lar
לוסרדקס 50
dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric
לוסרדקס 50
dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric
לוסרדקס 100
dexcel pharma technologies ltd - losartan potassium - קפליות - losartan potassium 100 mg - losartan - losartan - hypertension. losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losardex on the primary deposite endpoi